Publications by authors named "Bettina Hanschke"
Introduction: Gastrointestinal (GI) toxicity is still an issue within drug development, especially for novel oncology drugs. The identification of GI mucosal damage at an early stage with high sensitivity and specificity across preclinical species and humans remains difficult. To date, in preclinical studies, no qualified mechanistic, diagnostic or prognostic biomarkers exist for GI mucosal toxicity.
View Article and Find Full Text PDFIntroduction: Gastrointestinal (GI) toxicity is still an issue within drug development, especially for novel oncology drugs. The identification of GI mucosal damage at an early stage with high sensitivity and specificity across preclinical species and humans remains difficult. To date, in preclinical studies, no qualified mechanistic, diagnostic or prognostic biomarkers exist for GI mucosal toxicity.
View Article and Find Full Text PDFArticle Synopsis
- BTK is a key enzyme involved in B-cell disorders, and targeting it has been shown to help treat these conditions.
- Researchers developed a new series of BTK inhibitors using an imidazo[4,5-b]pyridine design, leading to a promising compound with high potency and selectivity.
- The lead compound showed strong inhibitory effects in human blood and effective results in a rat model, along with good pharmacokinetic properties.